Leveraging the advanced nanotechnology, this newly designed pH‐sensitive nanocarrier introduces a precise CD73/adenosine inhibition within the acidic TME that reprograms the immune landscape in EGFR‐mutant NSCLC, which represents a promising therapeutic strategy to overcome immunotherapy resistance in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.